Proven for weeks and still live — safe to model.
Battle-tested: running 44 days across 2 GEOs. Surviving this long usually means it's profitable enough to keep funding.
Seen across Finland/Taiwan — the angle travels across these markets.
- Seen 44/30 days
- 2 GEOs
- Redirect chain checked
- LP host: genomeweb.com
Reverse-engineered from the live ad — longevity, GEOs, and the affiliate funnel behind it. Verified by following the redirect chain on Jun 16. Free, no login.
Funnel, reverse-engineered
The campaign behind this creative
← the actual path the money takes.
Creative
GenomeWeb | Sponsored
Landing page
genomeweb.com
where it lands
Product / Offer: not detected
Tracker: not detected
Affiliate network: not detected
How we know: the tracker and affiliate network come from the live redirect chain we followed and fingerprinted hop by hop. Greyed nodes weren’t detected.
Active
running 44d · last seen 2d ago · 2 markets
Running with a modest observed footprint so far.
Gravity
45/100
push pressure now · 30d index
Strength
29/100
overall scale · 30d index
Run
44d
last seen 2d ago
Markets
2
countries seen
Landing page
genomeweb.com
final host
Screenshot
—
not captured yet
Operator
—
unidentified
Network
Outbrain
traffic source
Genomic Screening Uncovers Actionable Results in Thousands of Exome-Sequenced MyCode Participants
GenomeWeb | Sponsored@genomeweb
Top 10% longevity in network
Days alive is a profitability proxy — advertisers don’t pay to run losers.
Geo reach
Multi-market2 marketsPredominantly Tier 1, concentrated in Europe — Finland.
- Tier 11/2
- Tier 31/2
Regions:Europe 1APAC 1
What the data shows
GenomeWeb | Sponsored's Outbrain creative has been running for 44 days across 2 countries and first seen on May 2, 2026 and last seen on June 16, 2026. It has been observed in Finland and Taiwan. The ad lands on genomeweb.com. On our 30-day observation series the creative has run in intermittent bursts over the last 30 days. GenomeWeb | Sponsored is running 8 other creatives we have indexed, linked below for side-by-side comparison.
Creative headline: Genomic Screening Uncovers Actionable Results in Thousands of Exome-Sequenced MyCode Participants. Indexed on Outbrain by mediabuyer.
Landing-page intelligence
Landing page intelligence
Where this ad lands
The lander is the product — screenshot, redirect chain, offer, tech stack, and on-page text in one place.
Landing page not captured yet
Our crawler renders each advertiser’s funnel on a rolling schedule. Recently observed ads are queued first — check back to see the full-page screenshot.
Host
genomeweb.com
Path
/sequencing/genomic-screening-uncovers-actionable-results-thousands-exome-sequenced-mycode
Full URL
Redirect chain
Chain not captured yet.
Final host: genomeweb.com. Hop-by-hop capture runs as a separate pipeline; ads observed in recent ingests get crawled first.
Tracking parameters
- utm_source
- outbrain
- utm_medium
- paid content
- utm_campaign
- outbrain_seracare
- obOrigUrl
- true
+ 1 known tracker hidden (cloaker IDs scrubbed at ingest).
Tracking setup · Outbrain
Outbrain emits ob_click_id (your unique click), ob_source (publisher), ob_section (placement), and ob_position. Forward ob_click_id to your tracker as the postback key. ob_source and ob_section are the two highest-signal sub-IDs for blacklisting.
?ob_click_id={ob_click_id}&ob_source={ob_source}&ob_section={ob_section}&ob_position={ob_position}Default Outbrain setup template: ?ob_click_id={ob_click_id}&ob_source={ob_source}&ob_section={ob_section}&ob_position={ob_position}
Tech stack
No third-party monetization stack detected — this appears to be a direct landing page.
Landing page hubs
Landing page text
On-page text not extracted yet.
Observed daily (last 30 days)
May 19 → Jun 17·peaks Jun 16
30-day run pattern
PulsedIntermittent runs with quiet stretches — likely paused for budget cycles or rotation against fresher creatives.
- Coverage
- 3% of 30d
- Peak surge
- 1× vs median
- Last 7d
- 1
- WoW
- new
Peak day:
Window: May 19 → Jun 17
Sibling creatives from this campaign
Other creatives in Other on Outbrain
The rest of the set they’re running — see what else this angle is paired with.
Clinical Sequencing Can Enable Preemptive Medicine, but Hurdles Remain, Says Illumina's Damon Hostin
ctDNA Useful for Deescalating Breast Cancer Treatment in Older Women, U of Pittsburgh Study Finds
Legal Ruling on FDA Authority Over LDTs Raises Questions for Advanced Dx, CDx Developers
Leukemia Trial to Assess DNA Methylation, Mutation Tests to Stratify Patients
The Eligible but Under-Tested: Genomic Medicine in 2026 With Illumina's Damon Hostin
Polygenic Risk Scores Augmented Other Clinical Factors for a Range of Indications in 2025
ASCO: Razor Genomics Test Shows Promise for Chemotherapy Selection in High-Risk Lung Cancer Patients
Pathway to Medicare Coverage for MCED Tests Included in Federal Spending Package
Tested headline variants8
Tested headline variants
GenomeWeb | Sponsored's own A/B test — which headline they kept
The advertiser’s own A/B result, handed over: ranked by days running, the survivor on top. Variants they stopped running are struck through — they tested and killed those angles.
- #1ASCO: Razor Genomics Test Shows Promise for Chemotherapy Selection in High-Risk Lung Cancer PatientsWinning angle56d13 content tokens
- #2ctDNA Useful for Deescalating Breast Cancer Treatment in Older Women, U of Pittsburgh Study Finds44d11 content tokens
- #3Polygenic Risk Scores Augmented Other Clinical Factors for a Range of Indications in 202539d10 content tokens
- #4Leukemia Trial to Assess DNA Methylation, Mutation Tests to Stratify Patients31d9 content tokens
Winning angle: the headline they kept alive longest — it beat the other variants they tested. Model this one; treat the rest as discarded experiments.
More from GenomeWeb | Sponsored8
More from GenomeWeb | Sponsored
Most spy tools stop at the creative. This page connects it to the campaign behind it — the funnel, the longevity, the GEOs. Free.